NLRX1 and myocardial ischemia: Given that specific NLRX1 agonists are currently in development [75] evaluating these compounds within the recently established small-animal multicenter consortium—designed to test cardioprotective agents against acute cardiac ischemia–reperfusion injury (IRl) [24, 33, 36] appears to be a valuable approach.